The Value-Based Care Solutions Group, recently acquired by Veritas Capital from GE Healthcare, today announced its rebranding to Virence Health Technologies. The company is a leading software provider that leverages technology and analytics to help healthcare providers across the continuum of care effectively manage their financial, clinical and human capital

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated